Dan Kalshan, MD
Internal Medicine · San Francisco, CANPI 1326033200
Payments from drug & device makers
Across 157 payments — averaging $23.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$756
- AbbVie$520
- Gilead$332
- Viiv Healthcare Company$172
- Biohaven Pharmaceutical Holding Company Ltd.$149
- plus $474 from 7 others
What the payments were for
- Food & beverage$3,646100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 37 | $1,261 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $756 |
| AbbVie(2 entities) | 31 | $520 |
| Gilead | 9 | $332 |
| Viiv Healthcare Company | 8 | $172 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $149 |
| Indivior Inc. | 2 | $127 |
| AstraZeneca | 6 | $98 |
| Shire North American Group Inc | 4 | $98 |
| Currax Pharmaceuticals LLC | 4 | $61 |
| Novo Nordisk | 3 | $56 |
| Pfizer | 1 | $21 |
| Nalpropion Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,663 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 11 | $15,286 |
| Liothyronine Sodium | 24 | $1,135 |
| Testosterone Cypionate | 12 | $640 |
| Olmesartan Medoxomil | 26 | $511 |
| Atorvastatin Calcium | 39 | $475 |
| Levothyroxine Sodium | 34 | $445 |
| Oxycodone Hcl | 52 | $409 |
| Hydromorphone Hcl | 11 | $365 |
| Metoprolol Succinate | 16 | $304 |
| Losartan Potassium | 18 | $195 |
| Zolpidem Tartrate | 30 | $195 |
| Bupropion XlBupropion Hcl | 15 | $180 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $171 |
| Diclofenac Sodium | 16 | $165 |
| Clonazepam | 16 | $119 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in San Francisco
- Rahul AggarwalSan Francisco$24M
- Thomas MartinSan Francisco$13.7M
- Peter HuntSan Francisco$9.8M
- Diane HavlirSan Francisco$8.4M
- Sandy WongSan Francisco$6.6M
- Nina ShahSan Francisco$5.4M
- Katy TsaiSan Francisco$3.8M
- Riley BoveSan Francisco$3.6M
- Jacob LalezariSan Francisco$3.3M
- Flavio VincentiSan Francisco$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.